Related Experiment Video
Updated: Jun 22, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Engineered therapeutic antibodies with improved effector functions.
Tsuguo Kubota1, Rinpei Niwa, Mitsuo Satoh
1Antibody Research Laboratories, Kyowa Hakko Kirin Co., Ltd, Machida-shi, Tokyo, Japan.
Cancer Science
|June 23, 2009
Summary
Advanced Fc engineering enhances therapeutic antibody effector functions, potentially improving antitumor activity and reducing treatment costs. This review explores methods ready for clinical trials to boost antibody efficacy.
Area of Science:
- Immunology
- Biotechnology
- Pharmacology
Background:
- Over 20 therapeutic antibodies approved in the last decade, with many more in development.
- Fc-dependent functions like ADCC, CDC, and prolonged half-life are key to antibody efficacy.
- Current antibody therapies face challenges with efficacy and high costs.
Purpose of the Study:
- To review advanced Fc engineering strategies for enhancing antibody effector functions.
- To explore methods for improving antitumor activity and therapeutic outcomes.
- To identify Fc engineering approaches ready for clinical evaluation.
Main Methods:
- Review of scientific literature on Fc engineering techniques.
- Analysis of mechanisms underlying Fc-dependent antibody functions (ADCC, CDC, half-life).
- Focus on Fc domain interactions with FcgammaRIIIa, C1q, and neonatal Fc receptor.
Main Results:
- Fc engineering offers a viable strategy to overcome limitations of current antibody therapies.
- Enhanced effector functions can lead to improved antitumor activity.
- Engineered antibodies may allow for reduced therapeutic doses and lower costs.
Conclusions:
- Advanced Fc engineering holds significant promise for improving therapeutic antibody efficacy.
- Optimizing Fc-mediated functions can enhance antitumor responses.
- Several Fc engineering strategies are nearing clinical validation for improved cancer treatment.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...